Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Retained Earnings (2016 - 2025)

UroGen Pharma (URGN) has disclosed Retained Earnings for 10 consecutive years, with -$959.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 19.04% year-over-year to -$959.7 million, compared with a TTM value of -$959.7 million through Dec 2025, down 19.04%, and an annual FY2025 reading of -$959.7 million, down 19.04% over the prior year.
  • Retained Earnings was -$959.7 million for Q4 2025 at UroGen Pharma, down from -$933.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $143000.0 in Q1 2021 and bottomed at -$959.7 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$420.2 million, with a median of -$481.5 million recorded in 2021.
  • The sharpest move saw Retained Earnings skyrocketed 111.21% in 2023, then tumbled 6718616.67% in 2024.
  • Year by year, Retained Earnings stood at -$467.3 million in 2021, then surged by 99.98% to -$107000.0 in 2022, then surged by 111.21% to $12000.0 in 2023, then crashed by 6718616.67% to -$806.2 million in 2024, then fell by 19.04% to -$959.7 million in 2025.
  • Business Quant data shows Retained Earnings for URGN at -$959.7 million in Q4 2025, -$933.4 million in Q3 2025, and -$900.0 million in Q2 2025.